Middle-aged and elderly patients with lower urinary tract symptoms over 40 years old account for 70% of urology outpatients, including 30% of those aged 41-60 years old, and the development of lower urinary tract symptoms is a younger trend. Recently, the Chinese Medical Association Urology Branch, the Chinese Medical Association Urology Branch Urological Control Group, and the Chinese Overactive Bladder Diagnosis and Treatment Promotion Alliance released the results of the first survey on the status of lower urinary tract symptoms in urology outpatients in China. The clinical progress of BPH is mainly manifested by the aggravation of lower urinary tract symptoms, the most obvious feeling for patients is “inability to urinate” (incomplete urination, straining to urinate, thinning of urine stream and bifurcation of urine stream); overactive bladder syndrome is characterized by urinary urgency Overactive bladder syndrome is a syndrome characterized by symptoms of urinary urgency, which are often referred to as “inability to hold it in” (urinary urgency, frequency, nocturia, and urge incontinence). In this survey, 65.8% of outpatients with lower urinary tract symptoms were diagnosed with benign prostatic hyperplasia, overactive bladder, or benign prostatic hyperplasia with overactive bladder. Moreover, the results of this survey showed that 85% of patients with lower urinary tract symptoms had moderate to severe symptoms, thus indicating that the awareness of patients in China is currently weak and they often wait until their condition worsens before going to the hospital, thus missing the best time for treatment. Another study showed that lower urinary tract symptoms caused anxiety in 35.9% of men and 53.3% of women, and depression in 29.8% of men and 37.6% of women. However, many patients are too shy to talk about it due to traditional beliefs and often miss the best time for treatment. For this reason, Wei Zhongqing called on patients to actively use tools such as the I-PSS and OABSS self-test forms to achieve self-diagnosis, and called on patients to seek early detection, treatment and medical attention. Zhongqing Wei also said, “Through the survey, it was found that drug treatment is the first choice for patients with lower urinary tract symptoms. In terms of treatment drug selection, doctors prefer alpha-blockers with a proportion of 58.2%, followed by anticholinergic drugs. While physicians commonly chose tamsulosin as the first-line agent among alpha blockers, solifenacin was commonly chosen among anticholinergic drugs.” Also according to the European Association of Urology (EΑU) “2012 Guidelines for the Treatment of Male LUTS” recommends that patients with moderate to severe LUTS with predominantly urinary storage phase symptoms should consider treatment with M receptor antagonists; alpha-blockers are recommended for moderate to severe male LUTS patients, and if both alpha-blocker and M receptor antagonist monotherapy do not provide good symptom relief, a combination of these two If both alpha-blockers and M-receptor antagonists do not provide good symptomatic relief, a combination of these two drugs may be considered.